|
Market Closed -
Nasdaq
04:00:00 2026-06-15 pm EDT
|
5-day change | 1st Jan Change | ||
| 23.50 USD | +0.09% |
|
-.--% | +159.10% |
| Jun. 16 | Assertio Holdings Completes Merger With Zydus Lifesciences | MT |
| Jun. 16 | Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026 | CI |
| Market Cap | 152M 135M 126M 115M 216M 14.6B 218M 1.52B 591M 7.46B 570M 558M 23.95B | P/E 2024 |
-3.79x | P/E 2025 | -1.91x |
|---|---|---|---|---|---|
| Enterprise Value | 129M 114M 107M 97.28M 183M 12.37B 185M 1.29B 501M 6.33B 483M 473M 20.3B | EV / Sales 2024 |
0.19x | EV / Sales 2025 | 0.3x |
| Free-Float |
99.05% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Assertio Holdings
| 1 day | +0.09% | ||
| 6 months | +22.33% | ||
| Current year | +159.10% |
| Current year | 9.11 | 23.5 | |
| 1 year | 8.61 | 23.5 | |
| 3 years | 7.71 | 39 | |
| 5 years | 7.71 | 120.15 | |
| 10 years | 7.71 | 1,569 |
| Director | Title | Age | Since |
|---|---|---|---|
Ravi Yadavar
BRD | Director/Board Member | 26 | 2026-06-15 |
Punit Patel
BRD | Director/Board Member | - | 2026-06-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/13/26 | Don | Chairman | -13,332 | 0.2069% | ||
| 5/5/26 | Free | Chairman | 4,851 | 0.0753% | ||
| 5/5/26 | Free | Director | 4,851 | 0.0753% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.09% | -.--% | +72.26% | -38.08% | 152M | ||
| -0.61% | -3.43% | +36.07% | +115.04% | 1,019B | ||
| -1.02% | -5.60% | +35.72% | +64.63% | 617B | ||
| +1.11% | -0.58% | +12.36% | +77.95% | 464B | ||
| +0.34% | -3.01% | +61.79% | +41.24% | 356B | ||
| -0.95% | -4.05% | +20.54% | +41.71% | 333B | ||
| -1.46% | -2.89% | +10.57% | +32.81% | 267B | ||
| -1.35% | -5.43% | -6.17% | +8.98% | 244B | ||
| -1.04% | -2.79% | +35.30% | +51.84% | 218B | ||
| -1.87% | -4.10% | +28.44% | +93.66% | 179B | ||
| Average | -0.68% | -3.16% | +30.69% | +48.98% | 369.73B | |
| Weighted average by Cap. | -0.60% | -3.54% | +29.07% | +70.56% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 125M 111M 104M 94.45M 178M 12.01B 180M 1.25B 486M 6.14B 469M 459M 19.71B | 119M 105M 98.45M 89.73M 169M 11.41B 171M 1.19B 462M 5.83B 446M 436M 18.72B |
| Net income | -21.58M -19.17M -17.9M -16.31M -30.76M -2.07B -31.05M -217M -83.92M -1.06B -81.03M -79.27M -3.4B | -30.38M -26.99M -25.19M -22.96M -43.3M -2.92B -43.7M -305M -118M -1.49B -114M -112M -4.79B |
| Net Debt | -59.79M -53.12M -49.58M -45.19M -85.23M -5.75B -86.02M -600M -233M -2.94B -224M -220M -9.43B | -23.15M -20.57M -19.2M -17.5M -33M -2.23B -33.31M -232M -90.03M -1.14B -86.92M -85.04M -3.65B |
Employees
53
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ASRT Stock
Select your edition
All financial news and data tailored to specific country editions
















